Unzyme Proving Grounds Epsilon
Helsinki, Finland (60.2055° N, 24.6559° E)
Overview
UPG Epsilon complements our Delta facility in the Helsinki region, providing dedicated infrastructure for pharmaceutical and consumer-grade enhancement testing. While Delta focuses on social integration studies, Epsilon specializes in controlled clinical environments with rapid access to urban medical resources.
Capabilities
- Next-generation containment systems
- AI-assisted subject monitoring
- Rapid response infrastructure
- Cross-border coordination capabilities
- Advanced biohazard management
- Mass trial capacity
Expansion Milestone
The establishment of UPG Epsilon marks a significant milestone in Unzyme Laboratories’ European growth strategy. This facility will dramatically increase our trial capacity while positioning us at the heart of the Central European market.
Construction Status
Facility construction is proceeding ahead of schedule. Primary containment structures are complete, with monitoring systems currently being installed. Staff recruitment is underway, with positions available for qualified candidates in security, research, and operations.
Regional Partnership
Unzyme Laboratories has established productive relationships with Polish authorities and local communities. Our investment represents one of the largest foreign direct investments in the Wrocław region, creating hundreds of high-skilled employment opportunities.
Future Capabilities
UPG Epsilon is designed to support the next generation of enhancement trials, including technologies currently in advanced development. The facility’s modular architecture allows for rapid expansion as our research portfolio grows.
For media inquiries regarding our Polish expansion, please contact our European Communications Office.